#InSilico
Insilico Medicine's AI-designed cancer drug ISM6331 is already in human trials. In October 2026, the company reported early tumor responses in patients with advanced mesothelioma. It's a small Phase 1 study, not a proven cure, but that's real clinical research. 2/4
November 17, 2026 at 4:17 AM
NAD+ drops ~50% by age 60. Insilico Medicine's AI targets that pathway. Trial data exists. We scored it: rigorous in some cohorts, preliminary in most. The hospitals getting AI right saw this coming. Come join them at TheLEDGR.io.

theledgr.io/join
November 15, 2026 at 6:05 PM
The best use of AI is medicine.

Drug discovery to a candidate used to take 3 to 6 years. Insilico says it did one in about 18 months.

Screening workload is down 44%, with 29% more cancers found.
November 13, 2026 at 6:57 PM
"Companies like Insilico Medicine and Recursion have demonstrated that AI can compress the early discovery phase from five or more years down to just months."

— from "How AI Is Transforming Drug Discovery in 2026"
How AI Is Transforming Drug Discovery in 2026
Companies like Insilico Medicine and Recursion have demonstrated that AI can compress the early discovery phase from five or more years down to just months.
theaiprism.com
November 12, 2026 at 12:10 PM
Grok Bot + superintelligence + longévité + AI, un bien beau combo tech bros trumpisés dans ce CP de la techbio américaine Insilico insilico.com/news/pr9a97f...
Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research
Insilico announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si.
insilico.com
November 10, 2026 at 9:59 AM
Insilico Medicine Announces Open-Source Longevity Grok AI System
Insilico Medicine announced Longevity Grok on November 6, 2026, an open-source system that uses up to 30 AI agents on Grok Bot to organize fragmented health records, propose interventions and score later biomarker results. The clinical-stage generative AI drug discovery company developed the project with Harvard Medical School researcher David Sinclair and paired the personal assistant with an opt-in aging-research network. The Longevity Grok product site dates the client and Mothership repositories’ public posting to October 30, 2026, and version 0.2.0 to November 5, 2026. That release added Research Autopilot, Clinic and Lab teams, renamed bots and delivery receipts. The November 6 announcement therefore formalized a product whose code was already public, rather than marking its first posting. The software is free under an MIT license but requires an xAI Grok Bot account. Onboarding starts by telling the bot to follow the public plsi.md setup file. The individual tier is available; physician Clinic tools and researcher Lab tools are rolling out by invitation through early-access requests. From Records to Scored Predictions At the center is PLSI, short for Personal Longevity Superintelligence, the orchestrator users talk to. The PLSI repository describes eight always-on core bots, 13 optional specialists and four bots...
www.unite.ai
November 7, 2026 at 10:19 AM
SHARE MY LATEST BEYOND THE LAB ARTICLE !

AI Could Speed Up Drug Discovery and Cut Research Costs. Will Patients See the Savings, or Will Drugmakers and Insurers Keep the Profits?

www.linkedin.com/pulse/beyond...
Beyond the Lab: AI’s Search for the Next Breakthrough Drug
Introduction Artificial intelligence is helping scientists develop new medicines by narrowing the search for promising treatments. On July 7, 2026, Insilico Medicine announced that an experimental dru...
www.linkedin.com
November 9, 2026 at 4:27 PM
'Yet only a few AI-native biotechs—such as Insilico Medicine and Generate Biomedicines—have gotten drugs into late-stage patient testing and the Food and Drug Administration hasn’t cleared any of them yet.
November 7, 2026 at 12:50 AM
Week in AI-bio: J&J's Rybrevant Faspro won accelerated approval in 2L head and neck cancer, MetaVia's DA-1726 cut liver fat 68%, Insilico launched Longevity Grok, and T-Therapeutics raised $133M.
https://openbionews.com/analysis/ai-in-bio-weekly-review-2026-10-31-to-11-06/
AI in Bio Weekly Review: J&J
The seven-day window spanning October 31–November 6, 2026 delivered landmark regulatory milestones, clinical dual-incretin proof-of-concept, and major platform financings across computational biology: the FDA granted accelerated approval to Johnson & Johnson
openbionews.com
November 8, 2026 at 3:05 AM
You know, Rose Quartz from Steven Universe would probably look awesome in this style
Or maybe even Bardic RJ and his OCs
#StevenUniverse #KOH #KingsofHellgame #StrawberryOctopus #StrawberryOctii #SU #BardicRJ #InsilicoBRJ/insilico(BardicRJ)
Since people asked for it, Here is a general guide on how we design characters for Kings of Hell!

If you are looking to KoH'ify any of your 'sona's or OC's, this should help a lot with steering them to that iconic KoH look!
November 3, 2026 at 3:08 PM
Longevity vaccines? They're working on it! A vaccine stops a problem before it starts so curie.md/briefs/29957 this one will arm up T-cells to fight specific harmful cell types before they cause disease. (ex. senescent cells & more) A quick read with lots of potential.
AI-powered "longevity vaccines" aim to clear the root causes of aging
Insilico Medicine is betting that AI can help design vaccines that slow aging itself. The company's new Longevity Vaccines initiative uses engineered T-cells — guided by circular mRNA and targeted nan...
curie.md
November 3, 2026 at 2:41 AM
Insilico Medicine leader shares AI-driven drug discovery insights in Shanghai and Dubai
Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: "THE COMMODITIZATION TRAP: WHO WINS WHEN EVERYONE HAS THE SAME AI?" As generative AI tools become commoditized and model capabilities increasingly turn into "public infrastructure," true differentiation no longer lies in whether one has AI, but in how seamlessly AI is integrated into a full closed-loop workflow-from target discovery and molecular generation to clinical validation. Drawing on Insilico Medicine's engineering practices and external partnerships with the Pharma.AI platform, Dr. Wang will share her perspectives on the competitive landscape in the "era of AI commoditization." She will highlight that data assets, automated experimental feedback loops, expert models, and tangible pipeline deliverables are the true keys to overcoming the commoditization trap. As Head of Global Business Development, she will also provide front-line insights into cross-border transactions and partnering models in AI-driven drug discovery. About the China Healthcare Summit Jointly hosted by BioCentury, BayHelix, and McKinsey & Company, the China Healthcare Summit has been held annually in Shanghai for more than a decade...
www.news-medical.net
October 30, 2026 at 8:25 PM
Insilico Medicine leader shares AI-driven drug discovery insights in Shanghai and Dubai
Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: "THE COMMODITIZATION TRAP: WHO WINS WHEN EVERYONE HAS THE SAME AI?" As generative AI tools become commoditized and model capabilities increasingly turn into "public infrastructure," true differentiation no longer lies in whether one has AI, but in how seamlessly AI is integrated into a full closed-loop workflow-from target discovery and molecular generation to clinical validation. Drawing on Insilico Medicine's engineering practices and external partnerships with the Pharma.AI platform, Dr. Wang will share her perspectives on the competitive landscape in the "era of AI commoditization." She will highlight that data assets, automated experimental feedback loops, expert models, and tangible pipeline deliverables are the true keys to overcoming the commoditization trap. As Head of Global Business Development, she will also provide front-line insights into cross-border transactions and partnering models in AI-driven drug discovery. About the China Healthcare Summit Jointly hosted by BioCentury, BayHelix, and McKinsey & Company, the China Healthcare Summit has been held annually in Shanghai for more than a decade...
www.news-medical.net
October 30, 2026 at 8:25 PM
Attacking a late-life-fatal lung disease may lead toward anti-aging for the rest of us & Insilico is investigating with their new drug trials. x.com/Tsubame33785... How sure is he? Well, he'll be the first to take it! Tweet has a 2 minute video & article is in English with sources.
Tsubame (@Tsubame33785667) on X
AIを活用した老化治療薬の開発が始まっている。Insilico MedicineのザボロンコフCEOによれば、開発中の薬で「老化時計」と呼ばれるバイオマーカーを逆転させることに成功したという。それがただちに寿命延長につながるとは限らないが、老化の逆転という夢の実現は案外早いかもしれない。 アレックス・ザボロンコフ「この薬の特別なところは、老化研究を通じて発見されたという点です。老化は、あなたにも私...
x.com
October 29, 2026 at 1:20 AM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains.
doi.org/10.1093/abt/...
#AI #insilico #Aibasedantibodydiscovery
October 26, 2026 at 1:49 PM
Δεν είναι χαζή η Eli Lilly που τους τελευταίους μήνες μονο εχει κλείσει σχετικες συμφωνίες πολλών δις (Insilico, Metis, Nvidia, κ.α.)
October 25, 2026 at 2:39 PM